# Piramal Pharma share price today (Piramal Pharma Ltd, NSE: PPLPHARMA)

> Piramal Pharma share price today: ₹233.69 at the NSE close on 3 November 2026, up 17.1% in a year. Piramal Pharma (NSE: PPLPHARMA) is worth ₹31,100 crore, trades at a P/E of 307.4 and has closed between ₹138.35 and ₹238.91 over the past 52 weeks. > Piramal Pharma Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. PPLPHARMA · Pharma - API & CRAMS · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/piramal-pharma-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹233.69 (+17.1% in a year)
- P/E: 307.4× (lower than 54% of the last 3 years)
- Revenue (Sep 2026): ₹2,617 Cr (+28.1% on a year ago)
- Profit (Sep 2026): ₹5.0 Cr
- Operating margin: 13.3% (+5.6 points on a year ago)
- ROCE: 3%, FY26
- ROIC: −22.2%, against a 12.0% cost of capital: −34.2 points
- Profit that came in as cash: 549%, last 3 years

The main question: the share price moved +17.1% in a year while yearly earnings per share moved −455.1%. The difference came from the market paying a higher multiple. ## What is the Piramal Pharma share price today? Piramal Pharma Ltd's share price was ₹233.69 at the close on 3 November 2026. It has been rising for 13 weeks. That is 23.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹138 and ₹239, and at that close it sat 95% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 17 weeks in a row. Over the last 4 years the share price moved +40% while the NIFTY 500 moved +44%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Piramal Pharma this quarter? 6 points on a year earlier and closed the week at a 52-week high. 1. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 15.7% to 14.4% of the company by the September 2026 quarter. 2. Operating margin up 5.6 points on a year earlier 13.3% in the September 2026 quarter, from 7.8%. Why: Margins rose because India and North America did well while costs were held. Next results: check whether order strength turns into sales in the stronger second half. From the earnings call on 28 Oct 2026. 3. Closed the week at a 52-week high ₹238.91 on 30 Oct 2026, the highest weekly close in a year. ## What are Piramal Pharma's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Piramal Pharma reported revenue of ₹2,617 crore, up 28.1% from ₹2,044 crore a year earlier, and a profit of ₹5.03 crore, against a loss of ₹99.2 crore a year earlier. ### Piramal Pharma results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹2,617 crore | ₹2,044 crore | +28.1% |
| Profit | ₹5.03 crore | loss of ₹99.2 crore | n/a |
| Earnings per share | ₹0.04 | ₹−0.75 | n/a |
| Operating margin | 13.3% | 7.8% | +5.6 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Piramal Pharma's management discussed these results on a call held on 28 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Piramal Pharma share price history? Piramal Pharma closed at ₹233.69 on 3 November 2026, up 17.1% from ₹199.63 a year earlier (31 October 2025) and up 123.3% over three years. Its highest weekly close since October 2022 was ₹281.95 on 1 November 2024. ### Piramal Pharma share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹191.07 | +22.3% |
| 1 month ago · 1 Oct 2026 | ₹197.97 | +18.0% |
| 6 months ago · 30 Apr 2026 | ₹161.87 | +44.4% |
| 1 year ago · 31 Oct 2025 | ₹199.63 | +17.1% |
| 3 years ago · 3 Nov 2023 | ₹104.65 | +123.3% |
| Earliest weekly close in our records · 21 Oct 2022 | ₹167.47 | +39.5% |
| Highest weekly close since October 2022 · 1 Nov 2024 | ₹281.95 | −17.1% |
| Lowest weekly close since October 2022 · 17 Mar 2023 | ₹65.48 | +256.9% |
| 52-week high (weekly close) · 30 Oct 2026 | ₹238.91 | −2.2% |
| 52-week low (weekly close) · 20 Mar 2026 | ₹138.35 | +68.9% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (218 weekly closes from 21 October 2022 to 3 November 2026.)

## What is the latest news on Piramal Pharma? 3 Nov 2026: Piramal Pharma closed at ₹233.69, up 22.3% on the week and up 18.0% on the month. 28 Oct 2026: Piramal Pharma held its results call for July to September 2026. Management guided: FY27 revenue growth approximately 19% to 20%. ### Earlier

- Results for July to September 2026: Revenue up 28.1% on a year earlier. ## What dividend does Piramal Pharma pay? Piramal Pharma paid no dividend in the 12 months to 4 November 2026. The last was a dividend of ₹0.14 a share, ex-date 16 July 2025. ### Piramal Pharma dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 16 Jul 2025 | ₹0.14 | Dividend |
| 12 Jul 2024 | ₹0.11 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 2 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Piramal Pharma Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 6 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Piramal Pharma management say on the latest results call? On the call for July to September 2026, held on 28 October 2026, Piramal Pharma's management guided: FY27 revenue growth approximately 19% to 20%. > “We now expect annual revenue growth of approximately 19% to 20%, with meaningfully higher growth in profitability.”
> Nandini Piramal, on the call for July to September 2026

### What management guided

- FY27 profitability growth meaningfully higher than revenue. - H2 stronger than H1 with momentum continuing on order visibility. - Full-year gross margin 64% to 65% average. - Innovation plus on-patent to exceed 50% of CDMO in next couple years. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/50510-28-Oct-2026.pdf). (From the call for July to September 2026, 28 October 2026.)

## What to watch in Piramal Pharma's next results? When Piramal Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Kenalog supply improving as new-CMO transfer moves through validation and submission - check availability update. - What to check (from the call)
- Kenalog supply improving as new-CMO transfer moves through validation and submission - check availability update. - Lexington staged milestones advancing with anchor cover for each phase - check go-live progress and demand signals. - Morpeth monthly updates moving toward timely resolution without major spend - check regulatory update and remediation progress. ## Which stock lists is Piramal Pharma on? Piramal Pharma is on 4 of our India lists: Momentum stocks, 52 week high & low, Small & mid cap stocks and Pharma stocks. - [Momentum stocks Market cap cr: 31941.465154242178](https://www.sectoralpha.in/momentum-stocks-india)
- [52 week high & low 52-week position: At 52-week high](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Small & mid cap stocks Size rank in India: 265](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 31941.465154242178](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Piramal Pharma profitable? Piramal Pharma Ltd earned ₹5.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹326 Cr. That is 0.2% of the quarter's revenue. The same quarter a year earlier lost ₹99.2 Cr. 6 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was −₹326 Cr (−458.2% on the year before). ## How much revenue does Piramal Pharma make, and is it growing? Piramal Pharma Ltd reported ₹2,617 Cr of revenue in the Sep 2026 quarter, +28.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 5 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹8,869 Cr. The last four reported quarters add to ₹9,779 Cr. FY26 revenue was ₹8,869 Cr, −3.1% on the year before. Recent pace: the last four quarters grew +10.6% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +9.4%, against +6.0% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Piramal Pharma keep? Piramal Pharma Ltd's operating margin was 13.3% in the Sep 2026 quarter, 5.6 percentage points higher than the same quarter a year ago. Across 6 years it has been between 9.0% and 23.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +5.6 percentage points on the year while gross margin changed −0.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Piramal Pharma's profit turning into cash? Over the last 3 years, 549% of Piramal Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,653 Cr of operating cash against −₹326 Cr of profit. After ₹1,505 Cr of spending on assets, ₹148 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 549% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Piramal Pharma's cash go? Piramal Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 155 days in FY26, up from 147 days in FY21. It spent ₹3,284 Cr on assets over the last 3 years. Customers take 89 days to pay, and stock sits for 345 days on average. At FY26 sales of ₹8,869 Cr, each day of that cycle ties up about ₹24.3 Cr, so roughly ₹3,766 Cr is tied up in the business at any time. FY26: customers took 89 days to pay and stock sat for 345 days, about 11.3 months of sales sitting as stock, for a full cycle of 155 days, longer than FY21's 147. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 345 days. Customers pay about 89 days after that. Suppliers are paid at 279 days. Together that makes the 155-day cycle. Spending on assets: ₹3,284 Cr over the last 3 years, against ₹2,388 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹1,100 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Piramal Pharma's P/E ratio, and how does it compare with its own history? Piramal Pharma Ltd's P/E is 307.4×, in the middle of its own history: higher than 46% of past readings. Its usual P/E (the middle reading) is 316.0×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −455.1% while the price moved +17.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +30.7% a year; about −39.3% a year came from earnings growth and about +70.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Piramal Pharma business getting better or worse? Piramal Pharma Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Piramal Pharma earn on its capital? Piramal Pharma Ltd earned a ROCE of 3% in FY26. That is up from a low of 2% in FY23. Its return on capital used (ROIC) is 34.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −3.7% net margin and 0.50× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −3.7% net margin × 0.50× asset turnover × 2.16× leverage (assets divided by equity) ≈ −4.0% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −22.2% − 12.0% = −34.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −22.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 0.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Piramal Pharma have too much debt? Piramal Pharma Ltd has total debt of ₹5,873 Cr against shareholder equity of ₹8,165 Cr as of Sep 2026, so its debt is 0.72× its equity. Year by year, that ratio went from 0.62 in FY22 to 0.70 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Piramal Pharma shareholding pattern? Foreign institutions cut their stake in Piramal Pharma Ltd by 18.1 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 13.7% of the company. Domestic institutions moved +0.6 points over the same period, to 14.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −18.1 points over 8 quarters, to 13.7%; Domestic institutions: +0.6 points over 8 quarters, to 14.4%; Promoters: −0.1 points over 8 quarters, to 34.8%. Why the owners changed: foreign institutions drove it (−18.1 points), with the other side taken by domestic institutions (+0.6 points). They reduced their stake. ## How far is Piramal Pharma from balance-sheet trouble? For Piramal Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Piramal Pharma rank in its industry? 44.6 out of 100, rank 16 of 24 in Pharma - API & CRAMS, with 71% of the evidence available. Piramal Pharma Ltd scores 44.6 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 16. Relative strength against the index is 40.9%, and revenue and profit growth are weak. The four parts add up to the total exactly: 17 + 2 + 10 + 15.6 = 44.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Piramal Pharma compared with? Piramal Pharma ranks 16 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 44.6 out of 100. 1. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) NEULANDLAB · leader · Most evidence points up · 96% evidence 76.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.3/35 · Revenue 78.3% · Profit 100% · Operating margin change 23 points · 88% evidence Capital efficiency 22.9/25 · ROCE 26.5% · Operating margin 35% · 100% evidence Valuation 14.1/20 · P/E 50.8× · PEG 1.04 · 100% evidence Relative strength 6.7/20 · Lead over its industry -7.8% · Lead over NIFTY 500 20.3% · 1 year 19.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 32.3 + 22.9 + 14.1 + 6.7 = 76 · What this means: Earnings are strong; relative strength in its sector is -7.8% and the one-year return is 19.6%. 2. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ACUTAAS · turning · Most evidence points up · 67% evidence 73.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.3/35 · Revenue 45.4% · Profit 95.5% · Operating margin change 9 points · 95% evidence Capital efficiency 20.3/25 · ROCE 31.6% · Operating margin 40% · 76% evidence Valuation 10.2/20 · P/E 74.6× · PEG n/a · 50% evidence Relative strength 12.1/20 · Lead over its industry n/a · Lead over NIFTY 500 59.6% · 1 year 131.7% · 25% evidence · 2 of 9 weeks ahead Exact sum: 31.3 + 20.3 + 10.2 + 12.1 = 73.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Laurus Labs Ltd](https://www.sectoralpha.in/stocks/laurus-labs-ltd) LAURUSLABS · leader · Most evidence points up · 93% evidence 71.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.9/35 · Revenue 23% · Profit 95.3% · Operating margin change 10 points · 100% evidence Capital efficiency 17.3/25 · ROCE 17.8% · Operating margin 34% · 100% evidence Valuation 5.8/20 · P/E 97× · PEG 2.98 · 65% evidence Relative strength 17.0/20 · Lead over its industry 42.3% · Lead over NIFTY 500 82.8% · 1 year 152.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.9 + 17.3 + 5.8 + 17 = 71 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Gland Pharma Ltd](https://www.sectoralpha.in/stocks/gland-pharma-ltd) GLAND · leader · Most evidence points up · 96% evidence 69.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 17.6% · Profit 46.4% · Operating margin change 3 points · 88% evidence Capital efficiency 16.0/25 · ROCE 15.1% · Operating margin 27% · 100% evidence Valuation 12.1/20 · P/E 44.6× · PEG 1.45 · 100% evidence Relative strength 16.8/20 · Lead over its industry 15.1% · Lead over NIFTY 500 49.3% · 1 year 60.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25 + 16 + 12.1 + 16.8 = 69.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [IOL Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/iol-chemicals-pharmaceuticals-ltd) IOLCP · leader · Most evidence points up · 100% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 26.7% · Profit 75% · Operating margin change 4 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.3% · Operating margin 14% · 100% evidence Valuation 13.9/20 · P/E 24.6× · PEG 0.66 · 100% evidence Relative strength 13.9/20 · Lead over its industry 21.6% · Lead over NIFTY 500 53.8% · 1 year 92.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.1 + 12.8 + 13.9 + 13.9 = 69.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) SHILPAMED · leader · Most evidence points up · 89% evidence 67.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.4/35 · Revenue 28% · Profit 100% · Operating margin change 1 points · 88% evidence Capital efficiency 10.8/25 · ROCE 10.9% · Operating margin 29% · 100% evidence Valuation 9.9/20 · P/E 65.7× · PEG 1.73 · 65% evidence Relative strength 19.9/20 · Lead over its industry 47.2% · Lead over NIFTY 500 84.2% · 1 year 170.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 26.4 + 10.8 + 9.9 + 19.9 = 67 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Morepen Laboratories Ltd](https://www.sectoralpha.in/stocks/morepen-laboratories-ltd) MOREPENLAB · leader · Evidence leans up · 85% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.8/35 · Revenue 30.1% · Profit 90.9% · Operating margin change 9 points · 100% evidence Capital efficiency 9.3/25 · ROCE 8.1% · Operating margin 16% · 100% evidence Valuation 8.5/20 · P/E 32.9× · PEG 2.14 · 100% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 94.5% · 1 year 139% · 25% evidence · 12 of 12 weeks ahead Exact sum: 31.8 + 9.3 + 8.5 + 12.5 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Divis Laboratories Ltd](https://www.sectoralpha.in/stocks/divis-laboratories-ltd) DIVISLAB · leader · Evidence leans up · 96% evidence 61.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.7/35 · Revenue 16.4% · Profit 26.8% · Operating margin change 11 points · 88% evidence Capital efficiency 18.6/25 · ROCE 22% · Operating margin 41% · 100% evidence Valuation 2.6/20 · P/E 87.1× · PEG 3.45 · 100% evidence Relative strength 15.5/20 · Lead over its industry 9.2% · Lead over NIFTY 500 43.1% · 1 year 45.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.7 + 18.6 + 2.6 + 15.5 = 61.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 9. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) GRANULES · turning · Evidence leans up · 96% evidence 57.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Revenue 24.8% · Profit 38.1% · Operating margin change 3 points · 88% evidence Capital efficiency 16.2/25 · ROCE 15.5% · Operating margin 23% · 100% evidence Valuation 10.2/20 · P/E 35.2× · PEG 1.29 · 100% evidence Relative strength 6.7/20 · Lead over its industry -5.2% · Lead over NIFTY 500 24.2% · 1 year 48.5% · 100% evidence · 7 of 12 weeks ahead Exact sum: 24.3 + 16.2 + 10.2 + 6.7 = 57.4 · What this means: Earnings are strong; relative strength in its sector is -5.2% and the one-year return is 48.5%. 10. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) SAILIFE · leader · Evidence leans up · 89% evidence 57.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 17.6% · Profit 48% · Operating margin change 3 points · 88% evidence Capital efficiency 17.0/25 · ROCE 19.6% · Operating margin 27% · 100% evidence Valuation 4.8/20 · P/E 90× · PEG 3.63 · 65% evidence Relative strength 13.8/20 · Lead over its industry 9.9% · Lead over NIFTY 500 42.9% · 1 year 69.6% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.7 + 17 + 4.8 + 13.8 = 57.3 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [SMS Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/sms-pharmaceuticals-ltd) SMSPHARMA · breaking out · Evidence leans up · 96% evidence 55.8 out of 100 Growth Capital Valuation Relative
12. [Blue Jet Healthcare Ltd](https://www.sectoralpha.in/stocks/blue-jet-healthcare-ltd) BLUEJET · quiet · Evidence leans up · 81% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Solara Active Pharma Sciences Ltd](https://www.sectoralpha.in/stocks/solara-active-pharma-sciences-ltd) SOLARA · breaking out · Evidence leans down · 74% evidence 49.5 out of 100 Growth Capital Valuation Relative
14. [Windlas Biotech Ltd](https://www.sectoralpha.in/stocks/windlas-biotech-ltd) WINDLAS · leader · Evidence leans down · 81% evidence 47.6 out of 100 Growth Capital Valuation Relative
15. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ANTHEM · leader · Evidence leans down · 89% evidence 46.7 out of 100 Growth Capital Valuation Relative
16. Piramal Pharma Ltd this page PPLPHARMA · leader · Evidence leans down · 71% evidence 44.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.0/35 · Revenue 9.4% · Profit -80% · Operating margin change 5.6 points · 74% evidence Capital efficiency 2.0/25 · ROCE 2.5% · Operating margin 13.3% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 6.6% · Lead over NIFTY 500 40.9% · 1 year 19.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17 + 2 + 10 + 15.6 = 44.6 · What this means: Relative strength against the index is 40.9%, and revenue and profit growth are weak. 17. [Supriya Lifescience Ltd](https://www.sectoralpha.in/stocks/supriya-lifescience-ltd) SUPRIYA · breaking out · Evidence leans down · 96% evidence 43.7 out of 100 Growth Capital Valuation Relative
18. [Concord Biotech Ltd](https://www.sectoralpha.in/stocks/concord-biotech-ltd) CONCORDBIO · quiet · Evidence leans down · 85% evidence 40.8 out of 100 Growth Capital Valuation Relative
19. [Jubilant Pharmova Ltd](https://www.sectoralpha.in/stocks/jubilant-pharmova-ltd) JUBLPHARMA · turning · Most evidence points down · 86% evidence 30.3 out of 100 Growth Capital Valuation Relative
20. [Hikal Ltd](https://www.sectoralpha.in/stocks/hikal-ltd) HIKAL · turning · Most evidence points down · 78% evidence 29.7 out of 100 Growth Capital Valuation Relative
21. [OneSource Specialty Pharma Ltd](https://www.sectoralpha.in/stocks/onesource-specialty-pharma-ltd) ONESOURCE · turning · Most evidence points down · 83% evidence 29.2 out of 100 Growth Capital Valuation Relative
22. [Syngene International Ltd](https://www.sectoralpha.in/stocks/syngene-international-ltd) SYNGENE · turning · Most evidence points down · 100% evidence 27.8 out of 100 Growth Capital Valuation Relative
23. [Cohance Lifesciences Ltd](https://www.sectoralpha.in/stocks/cohance-lifesciences-ltd) COHANCE · breaking out · Most evidence points down · 78% evidence 27.1 out of 100 Growth Capital Valuation Relative
24. [Dishman Carbogen Amcis Ltd](https://www.sectoralpha.in/stocks/dishman-carbogen-amcis-ltd) DCAL · basing · Most evidence points down · 64% evidence 27.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API & CRAMS](https://www.sectoralpha.in/sectors/pharma-api-crams), all 24 compared on one page. ## Which companies are close to Piramal Pharma in size? Piramal Pharma is the 7th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Anthem Biosciences, Sai Life Sciences and Acutaas Chemicals. Just below it: Neuland Laboratories, Granules India and Shilpa Medicare. ### Pharma - API & CRAMS companies close in size

1. [Anthem Biosciences Ltd](https://www.sectoralpha.in/stocks/anthem-biosciences-ltd) ₹46,689 crore
2. [Sai Life Sciences Ltd](https://www.sectoralpha.in/stocks/sai-life-sciences-ltd) ₹33,093 crore
3. [Acutaas Chemicals Ltd](https://www.sectoralpha.in/stocks/acutaas-chemicals-ltd) ₹32,778 crore
4. Piramal Pharma Ltd ₹31,807 crore
5. [Neuland Laboratories Ltd](https://www.sectoralpha.in/stocks/neuland-laboratories-ltd) ₹25,275 crore
6. [Granules India Ltd](https://www.sectoralpha.in/stocks/granules-india-ltd) ₹22,907 crore
7. [Shilpa Medicare Ltd](https://www.sectoralpha.in/stocks/shilpa-medicare-ltd) ₹18,690 crore

[All 24 Pharma - API & CRAMS companies, largest first](https://www.sectoralpha.in/sectors/pharma-api-crams#all-companies)

### Companies close in size in other industries

1. [Endurance Technologies Ltd](https://www.sectoralpha.in/stocks/endurance-technologies-ltd) ₹31,978 crore · Auto Ancillaries - Diversified
2. [P I Industries Ltd](https://www.sectoralpha.in/stocks/p-i-industries-ltd) ₹31,861 crore · Pesticides/Agrochemicals
3. Piramal Pharma Ltd ₹31,807 crore
4. [Dhoot Transmission Ltd](https://www.sectoralpha.in/stocks/dhoot-transmission-ltd) ₹31,611 crore
5. [NLC India Ltd](https://www.sectoralpha.in/stocks/nlc-india-ltd) ₹31,608 crore · Power - Generation/Distribution

## What else do people ask about Piramal Pharma? ### What is Piramal Pharma's share price today? Piramal Pharma Ltd's share price is ₹233.69, +17.1% over the past year. The whole company is worth ₹31,100 Cr on the market. In the last 52 weeks it traded between ₹138 to ₹239; today it is 95% of the way up from the low, 23.5% above its 200-day average (as of 3 November 2026). ### What were Piramal Pharma's latest quarterly results? Piramal Pharma Ltd reported revenue of ₹2,617 Cr and net profit of ₹5.0 Cr for the Sep 2026 quarter. Earnings per share were ₹0.04. The operating margin was 13.3%, 5.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Piramal Pharma's market cap? Piramal Pharma Ltd's market capitalisation is ₹31,100 Cr at a share price of ₹233.69. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Piramal Pharma performing? Piramal Pharma Ltd's share price has been rising for 13 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 17 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Piramal Pharma's share price go up? This page does not forecast Piramal Pharma Ltd's share price. What it shows instead: the share price is ₹233.69, and it has been rising for 13 weeks. Its P/E of 307.4× is higher than 46% of its own last 3 years (as of 3 November 2026). ### Who owns Piramal Pharma? Promoters own 34.8% of Piramal Pharma Ltd, foreign institutions 13.7%, domestic institutions 14.4% and the public 36.7% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 18.1 percentage points over 8 quarters (as of 3 November 2026). ### Does Piramal Pharma have too much debt? Piramal Pharma Ltd has a moderate amount of debt: its debt is 0.70× its equity, and its operating profit is 3 times its interest bill. FY26 borrowings were ₹5,675 Cr against equity of ₹8,162 Cr. Keep that borrowing in mind when reading the returns on this page (as of 3 November 2026). ### Is Piramal Pharma's profit real cash? Yes, over the last 3 years, 549% of Piramal Pharma Ltd's reported profit came in as cash from operations. The latest year was lower at -507%, so the trend is worth watching. In FY26, operating cash was ₹1,653 Cr against reported profit of −₹326 Cr. Most of that cash then goes into a mix of the daily operating cycle and new capacity. These are yearly figures (as of 3 November 2026). ### Where is Piramal Pharma in its business cycle? Piramal Pharma Ltd's FY26 operating margin was 10.0%, against a 6-year range of 9.0% to 23.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 13.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Piramal Pharma story? The main question: the share price moved +17.1% in a year while yearly earnings per share moved −455.1%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Piramal Pharma a stock worth studying right now? What the numbers show: Piramal Pharma Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Piramal Pharma share price forecast for 2026? What management itself guided: FY27 revenue growth approximately 19% to 20%. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.